The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...
Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...
The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or ...
MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...
Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...
El-Khoueiry, MD, an associate professor of clinical medicine in the Division of Medical Oncology and director of the phase I ...
1. Malandrakis, P. Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study. Presented ...
A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in ...
Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer. Adding immunotherapy to platinum-based chemotherapy is an established standard of care for ...
The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback